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Abstract
Background: Serine hydrolases (SHs) are a functionally diverse family of enzymes playing pivotal roles in health
and disease and have emerged as important therapeutic targets in many clinical conditions. Activity-based protein
profiling (ABPP) using fluorophosphonate (FP) probes has been a powerful chemoproteomic approach in studies
unveiling roles of SHs in various biological systems. ABPP utilizes cell/tissue proteomes and features the FP-
warhead, linked to a fluorescent reporter for in-gel fluorescence imaging or a biotin tag for streptavidin enrichment
and LC-MS/MS-based target identification. Existing ABPP approaches characterize global SH activity based on
mobility in gel or MS-based target identification and cannot reveal the identity of the cell-type responsible for an
individual SH activity originating from complex proteomes.
Results: Here, by using an activity probe with broad reactivity towards the SH family, we advance the ABPP
methodology to glioma brain cryosections, enabling for the first time high-resolution confocal fluorescence
imaging of global SH activity in the tumor microenvironment. Tumor-associated cell types were identified by
extensive immunohistochemistry on activity probe-labeled sections. Tissue-ABPP indicated heightened SH activity in
glioma vs. normal brain and unveiled activity hotspots originating from tumor-associated neutrophils (TANs), rather
than tumor-associated macrophages (TAMs). Thorough optimization and validation was provided by parallel gel-
based ABPP combined with LC-MS/MS-based target verification.
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Conclusions: Our study advances the ABPP methodology to tissue sections, enabling high-resolution confocal
fluorescence imaging of global SH activity in anatomically preserved complex native cellular environment. To
achieve global portrait of SH activity throughout the section, a probe with broad reactivity towards the SH family
members was employed. As ABPP requires no a priori knowledge of the identity of the target, we envisage no
imaginable reason why the presently described approach would not work for sections regardless of species and
tissue source.
Keywords: Activity-based protein profiling (ABPP), Brain cryosection, Glioblastoma multiforme (GBM),
Immunohistochemistry, Serine hydrolase activity, Neutrophil serine protease (NSP), TAMRA-FP probe, Tumor-
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Background
The serine hydrolases (SHs) form a diverse family of en-
zymes with a predicted number of ∼240 in humans, falling
into two subfamilies: the serine proteases (∼125 members)
and the metabolic SHs (mSHs ∼115 members) [1, 2]. The
mSHs include small-molecule hydrolases, such as lipases,
esterases and amidases and utilize a conserved serine nu-
cleophile to hydrolyze amide, ester, and thioester bonds in
different types of substrates including metabolites, lipids
and peptides. Importantly, SHs have emerged as thera-
peutic targets in diseases such as cancer, obesity, diabetes,
and neurological diseases [3].
The advent of chemoproteomic techniques some 20
years ago, activity-based protein profiling (ABPP) in par-
ticular, allowed for the first time proteome-wide profiling
of SH activity in cells and tissue homogenates [4]. The
prototype activity probe for SHs features the active site-
targeted warhead, typically a fluorophosphonate (FP),
linked to a fluorescent reporter allowing in-gel imaging of
SH activity in proteomes after SDS-PAGE separation. An
advanced platform combining ABPP and multidimen-
sional protein identification techniques (ABPP-MudPIT)
was introduced to facilitate high-content functional prote-
omics discovery of potential new markers of human dis-
eases [5].
In the comparative mode, ABPP enables comparison
of SH activity pattern between different proteomes, e.g.
aggressive vs. non-aggressive cancer cells [6]. Indeed,
such studies have highlighted previously unrecognized
importance of SH family members as metabolic nodes
orchestrating the availability of lipids involved in onco-
genic signaling.
In the competitive mode, ABPP has proven its power in
the discovery and selectivity testing of novel inhibitors tar-
geting individual SHs [7]. In this approach, the proteome
is first treated with the inhibitor (commonly a serine-
nucleophile targeting covalent inhibitor), binding of the
inhibitor masks the active site, preventing subsequent la-
beling with the activity probe. EnPlex, an advanced high-
throughput platform based on ABPP principles has been
introduced as a feasible approach for SH superfamily-wide
selectivity profiling that could be incorporated into the
early stage of drug discovery [8].
ABPP can also serve a powerful platform for mass-
spectrometry (MS) -based target identification from
complex proteomes. In this case, the FP-warhead is
linked to a biotin tag, enabling streptavidin enrichment
and subsequent LC/MS-MS-based target identification.
Current ABPP approaches characterize global SH
activity based on mobility in gel or MS-based target
identification from homogenates and cannot reveal
the identity of the cell-types responsible for an indi-
vidual SH activity originating from complex pro-
teomes, suggesting that the full potential of this
technology may not have yet been harnessed. To date,
quenched activity probe-based live cell fluorescence
imaging has been described for a handful of prote-
ases, such as cysteine cathepsins [9]. The quenched
fluorescent probes were applied for labeling of active
proteases in fresh-frozen cancer tissues [10], for
macrophage detection in atherosclerotic plaques [11],
and as a diagnostic tool to image skin tumor margins
[12]. Recently, a small-molecule chemical toolbox was
constructed for parallel imaging of human neutrophil
serine proteases (NSPs). The toolbox comprised
activity-probes with different fluorophores showing
minimal wavelength overlap and highly selective nat-
ural and unnatural amino acid recognition sequences
tailored for the four individual NSPs [13]. This ele-
gant approach enabled for the first-time simultaneous
imaging of the four NSPs in living neutrophils by
fluorescence microscopy.
We reasoned that ABPP-based imaging of SH activ-
ity should be feasible at high resolution in complex
native proteomes such as brain tissue while preserving
the anatomical details of this delicate organ. Brain
cryosections serve as fascinating premise to directly
explore this issue as functional responses such as
receptor-stimulated G protein activity and mSH-
regulated endocannabinoid tone can be readily moni-
tored in brain cryosections without compromising the
anatomical integrity [14, 15].
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Here, by using an activity probe with broad reactivity to-
wards the SH family, we advance the ABPP methodology
to glioma brain cryosections, enabling high-resolution
confocal fluorescence imaging of global SH activity in gli-
oma brain with well-preserved cyto-architecture. We un-
veil heightened SH activity in the tumor, as compared to
healthy brain. Heterogeneous distribution pattern of SH
activity within the tumor microenvironment was explored
in detail by identification of the glioma-associated cell
types using immunohistochemical markers. Cross-
validation was provided by classical gel-based ABPP using
homogenates of healthy brain and glioma, as well as by
LC/MS-MS-based target identification. These studied re-
vealed quite unexpectedly that SH activity hotspots in gli-
oma originate from tumor-associated neutrophils (TANs),
rather than tumor-associated macrophages (TAMs). We
anticipate that tissue-ABPP should enable a wide range of
applications for high-resolution confocal imaging of global
SH activity in practically any type of tissue and species,
opening new avenues for cellular and subcellular
localization of SH activity in complex proteomes with pre-
served anatomy.
Results
The principal motivation for this work was to extend the
utility of ABPP towards applications enabling high-
resolution imaging of global SH activity in cryosections
of complex proteome, namely glioma brain, while pre-
serving the delicate cyto-architecture of the tumor
microenvironment. We chose to use a promiscuous ac-
tivity probe for these studies in order to portrait the glo-
bal SH activity profile in glioma brain sections. The
tissue- and gel-based ABPP approaches that were uti-
lized in this study are illustrated in Figure S1.
The Glioma Model
Glioblastoma multiforme (GBM) is the most malignant
and most frequent brain tumor accounting for more
than 65% of all cases [16]. As the name implies, GBMs
have a wide spectrum of histological morphologies ran-
ging from small-cell type to very pleomorphic giant-cell
forms with poor differentiation and gliosarcomas [16,
17]. We used the rat syngeneic BT4C gliosarcoma model
[18] in which the glioma grows in a sarcomatous pattern
and is typically composed of a pleomorphic population
of tumor cells (Figure S2). We imaged tumors in vivo
22–24 days after implantation using MRI (Figure S3) and
animals were sacrificed 5–11 days later. Brain tissue was
excised from saline-perfused animals and used for cryo-
sectioning (tissue-ABPP) or preparation of homogenates
that were used in cross-validation experiments by gel-
ABPP. Animals of both sexes were used.
Optimization and Validation of ABPP Protocol for Brain
Cryosections
As our ultimate goal was to achieve high-resolution im-
aging of SH activity in cryosections without significantly
compromising anatomical integrity, we considered fix-
ation necessary to preserve delicate cyto-architecture. On
the other hand, fixation should be sufficiently mild in
order to preserve enzymatic activity, a prerequisite for the
probe to covalently label catalytically competent SHs. We
found that in contrast to acetone or methanol, fixation
with paraformaldehyde preserved tissue integrity and in-
hibitor sensitivity of TAMRA-FP labeling (Figure S4).
We chose 0.5 μM probe concentration as a comprom-
ise between signal intensity and cost-affordable probe
amount (Figure S5). Concerning assay buffer, we found
that for applications where maximal TAMRA-FP signal
is the desired final readout, Tris or phosphate buffer
(pH 7.4) without BSA supplementation is optimal. How-
ever, for applications where TAMRA-FP labeling step is
followed by immunohistochemistry, BSA is included to
block tissue prior to antibody addition (Figure S6).
Distribution and Overall Characteristics of TAMRA-FP
Signal in Glioma and Control Brain
As shown in Fig. 1, relatively intense and heteroge-
neously distributed TAMRA-FP labeling was evident
over the glioma. In general, TAMRA-FP fluorescence
was more intense over the glioma as compared to most
regions of the healthy brain. Nuclear DAPI staining indi-
cated dense cell population in glioma as compared to
most regions of the healthy brain. This likely partly ac-
counts for the heightened TAMRA-FP signal in glioma.
Intense TAMRA-FP labeling was evident also in cell-
dense structures of the healthy brain, such as hippocam-
pal pyramidal cell layer and granular layer of dentate
gyrus (Fig. 1a) and cerebellar Purkinje cell layer (Figure
S6). On the other hand, white matter tracts (Fig. 1a)
showed low TAMRA-FP labeling. Collectively these find-
ings indicate that under the conditions employed, the
method is sufficiently sensitive to allow imaging of
TAMRA-FP labeling not only over the tumor, but also
in various regions of the healthy brain.
Building on tissue-ABPP images of gliomas from different
animals, a common pattern of TAMRA-FP labeling
emerged and the following classification will be used to fa-
cilitate signal interpretation in forthcoming immunohisto-
chemistry. A common TAMRA-FP labeling pattern with
widest distribution over the glioma was characterized by
non-nuclear intense fluorescence originating from evenly
distributed individual cells (Fig. 1b, Video S1). In what fol-
lows, we define these cells “TAMRA-FP hotspots”. How-
ever, the most intense TAMRA-FP labeling pattern was
non-nuclear and originated from cell clusters with variable
size (Fig. 1c, Video S1). We define this labeling pattern
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“TAMRA-FP hotspot clusters”. In healthy cortex shown for
comparison, TAMRA-FP fluorescence was less intense and
mainly localized to cytosol and plasma membrane (Fig. 1d).
Probe Labeling of Tumor and Healthy Brain SHs is
Differentially Sensitive to SH Inhibitors
To assure that TAMRA-FP specifically reports SH activ-
ity under the conditions of tissue-ABPP, we used the
competitive approach testing a panel of serine-
nucleophile targeting broad-spectrum inhibitors, con-
taining either FP [DeBi-FP (desthiobiotin-FP), MAFP
(methyl arachidonyl fluorophosphonate), IDFP (isopro-
pyl dodecylfluorophosphonate)] or sulfonylfluoride
[AEBSF (aminoethylbenzenesulfonyl fluoride), PMSF
(phenylmethylsulfonyl fluoride)] as the warhead. Inhibi-
tors were purposely used at maximally effective
Fig. 1 (See legend on next page.)
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concentrations to ensure comprehensive blockade of SH
activity prior to TAMRA-FP labeling. As evident from
Fig. 2, desthiobiotin-FP sharing the warhead-linker moi-
ety with TAMRA-FP, effectively inhibited TAMRA-FP
binding throughout the brain section, although weak re-
sidual labeling was evident as sparse spots over the gli-
oma. Further, treatment with PMSF and IDFP efficiently
prevented probe labeling in most brain regions, although
some residual signal persisted over the tumor. Intri-
guingly, while the mSH-inhibitor MAFP efficiently
blocked probe binding in most regions of the healthy
brain, it was less effective in preventing TAMRA-FP la-
beling of the tumor, indicating that while MAFP-
sensitive SH activity predominated in normal brain, SH
activity originating from glioma was rather insensitive to
this inhibitor. We considered this as a notable finding,
as MAFP is known to act as a pan-SH inhibitor potently
targeting the vast majority of mSHs [8]. When applied
to rat brain cryosections in a comparable setting, our
previous study indicated that MAFP (10 μM) was able to
comprehensively block mSH-mediated hydrolysis of the
major endocannabinoid 2-arachidonoylglycerol [14].
Comparative Gel-Based ABPP of SH Activity in
Homogenates of Glioma and Control Brain
We cross-validated the tissue-ABPP findings in gel-
based ABPP using homogenates of glioma and control
brain. In addition, we used rat cerebellar membranes to
facilitate comparison, as previous gel-based ABPP has
substantially relied on SH profiling in rodent brain
membrane proteomes [14, 19–27]. Building on such
studies from this and other laboratories [14, 19–27], we
could identify many of the SH bands based on inhibitor
sensitivity and mobility pattern in SDS-PAGE. These
studies revealed that while many of the SH bands were
common to the three proteomes (Fig. 3), brain-resident
SHs, including monoacylglycerol lipase (MAGL ~ 35
kDa) and KIAA1363 (~ 50 kDa) showed variable activity
in glioma. Both were proposed to play protumorigenic
role in various cancers [6]. While comparable activity
was evident for KIAA1363, MAGL showed low-to-non-
detectable activity in glioma, suggesting that it might not
play a major role in this glioma model. In addition, two
distinct mSHs, namely lysophospholipases A1 and A2
(LYPLA1/2 ~ 25 kDa) showed prominent, yet compar-
able activity in control brain and glioma. LYPLA1/2 are
depalmitoylases regulating membrane-association and
oncogenic signaling of Ras, and are inhibited by palmos-
tatin B ([28] and references therein).
Of note, the glioma possessed two prominent SH
bands migrating at ~ 25 and ~ 30 kDa (Fig. 3). It is note-
worthy that the respective SH bands showed low-to-
non-detectable activity in control brain. We verified that
the profile differences were present in homogenates
from seven glioma rats (Figure S7). Inhibitor profiling
revealed that the ~ 30 kDa band was sensitive to all
tested inhibitors whereas the ~ 25 kDa band was sensi-
tive to PMSF and deshiobiotin-FP, being resistant to
other inhibitors, including MAFP. Collectively, the tissue
and gel-based ABPP experiments suggest that MAFP-
resistant TAMRA-FP hotspots in the tumor likely re-
flects activity of the dominant ~ 25 kDa band, while the
bulk of MAFP-sensitive SH activity likely represent ac-
tivity of the ~ 30 kDa prominent SH band. Noteworthy,
in line with the outcome with glioma sections, PMSF ef-
ficiently prevented probe labeling of glioma homogenate
in gel-ABPP (Fig. 3). The gel-ABPP findings not only
cross-validate findings from tissue-ABPP but additionally
indicate that the SH activity profile of glioma is distinct
from that of normal brain and must therefore reflect ac-
tivity originating from cell types not normally residing in
brain.
Tissue-ABPP Combined with Immunohistochemistry
Enables Subcellular Localization of SH Activity within the
Tumor Microenvironment
The glioma is a highly heterogeneous cancer and con-
sists of several cell types, including tumor cells, endothe-
lial cells from angiogenic vessels, neurons, scar-forming
astroglia, as well as infiltrating monocytes/macrophages
(See figure on previous page.)
Fig. 1 Distribution and overall characteristics of TAMRA-FP signal in glioma and control brain. Note relatively intense and heterogeneously
distributed TAMRA-FP fluorescence over the glioma as compared to most regions of the healthy brain. Nuclear DAPI staining indicates dense cell
population in glioma as compared to most regions of the healthy brain. Note relatively intense TAMRA-FP and DAPI signal also in cell-dense
hippocampal pyramidal cell layer (py) and granular layer of dentate gyrus (GrDG) as well as relatively weak TAMRA-FP signal in white matter tracts
of corpus callosum (cc) (a), suggesting that the method offers sufficient sensitivity to enable imaging of TAMRA-FP fluorescence not only in the
tumor, but also in various regions of the healthy brain. Building on tissue-ABPP images of gliomas from different animals, a common pattern of
TAMRA-FP labeling was established: TAMRA-FP hotspots (b), characterized by intense and widely-distributed non-nuclear TAMRA-FP signal over
the glioma, originating from evenly distributed individual cells. We define the second pattern as TAMRA-FP hotspot clusters (c), characterized by
intense non-nuclear TAMRA-FP signal originating from cell clusters. In healthy cortical region shown for comparison (d), TAMRA-FP signal is less
intense and localizes mainly to cytosol and plasma membrane. The section illustrated here for TAMRA-FP and DAPI staining was further
immunostained for the phagocyte marker CD11b/c and is presented again (Figure S18). 3D-animation of merged TAMRA-FP-DAPI fluorescence
throughout the section thickness in TAMRA-FP hotspots (green lining) and TAMRA-FP hotspot clusters (yellow lining) is shown in
Supplementary Video 1
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that are recruited from the periphery [29–31]. We
approached this cellular complexity by immunohisto-
chemistry using various cell-type markers that were ap-
plied on TAMRA-FP labeled sections.
To visualize tumor cells, sections were stained for
Ki67, a nuclear marker of proliferating cell populations.
Proliferating scattered cell populations were detected in
glioma but as expected, were absent from healthy brain
(Figure S8). Ki67-positive cells showed poor co-
localization with TAMRA-FP hotspots or TAMRA-FP
hotspot clusters.
GFAP-positive astrocytes appeared as a dense cell
population encircling the tumor (Figure S9). Although
scattered GFAP-positive cells were detected within the
tumor, the bulk of tumor was devoid of astrocytes, in
line with previous findings with this model [29]. The
sparse presence of astrocytes is consistent with the
gliosarcoma character of this model [18]. Although
Fig. 2 Competitive tissue-ABPP demonstrating that TAMRA-FP reports SH activity in glioma brain sections. Sections were pretreated for 1 h with
the indicated concentrations of various serine-nucleophile targeting inhibitors and processed for TAMRA-FP labeling and confocal fluorescence
imaging as detailed in Materials and Methods. Sections from two individual rats bearing the tumor were used and images from two independent
experiments are shown as separate panels with DMSO control included in both experiments. Desthiobiotin-FP (5 μM) efficiently inhibits TAMRA-
FP labeling throughout the brain section. However, a weak residual signal persists as spots over the glioma tissue. Note absence of fluorescence
in the section processed without TAMRA-FP, indicating no detectable autofluorescence in the Cy3-window used for TAMRA-FP imaging. Note
that PMSF (1 mM), in contrast to AEBSF (1 mM), and IDFP (100 μM) both efficiently inhibit TAMRA-FP labeling throughout the brain sections, yet
leaving some residual activity over the tumor. Note in particular that MAFP (10 μM) efficiently inhibits probe labeling throughout the healthy
brain regions but only modestly inhibited labeling of TAMRA-FP hotspots in the tumor. However, partial MAFP-sensitivity of TAMRA-FP signal was
evident in tumors regions showing moderate probe fluorescence. The scale bars represent 1 mm. Images were adjusted for brightness
and contrast
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astrocytes showed moderate SH activity, TAMRA-FP
hotspots or TAMRA-FP hotspot clusters showed poor
co-localization with GFAP-positive cells. Throughout
the healthy brain, cells with star-shaped morphology (i.e.
astrocytes) were visible.
Tumor vasculature, visualized using the endothelial
markers von Willebrand factor and CD34, revealed rela-
tively low TAMRA-FP signal originating from endothe-
lial cells (Figure S10). However, TAMRA-FP hotspot
clusters resided often in the vicinity of the vessels. This
Fig. 3 Comparative and competitive gel-based ABPP reveals distinct SH activity profiles of glioma and healthy brain. Rat cerebellar membranes
were included as an additional control to facilitate SH band comparison and identification. Proteomes (1 mg/ml) were treated for 1 h with DMSO
or the indicated concentrations of the SH inhibitors, after which TAMRA-FP labelling was conducted for 1 h as detailed in Materials and Methods.
The reaction was quenched and 10 μg protein was loaded per lane and separated by SDS-PAGE. TAMRA-FP labeled bands appear as black after
in-gel imaging. Position of molecular weight markers (in kDa) is indicated on the gel. Based on previous studies from this and other laboratories
[14, 19–27] many healthy brain-resident SHs were identified, as indicated at left. Note comparable activities of KIAA1363 and LYPLA1/2 doublets
(black asterisk) in control brain and glioma. Note also prominent activity of MAGL doublet (double black asterisk) in control brain as opposed to
hardly detectable activity in glioma. Note that the glioma contains two prominent SH bands, migrating at ~ 25 and ~ 30 kDa (white asterisks). It is
noteworthy that the respective SH bands show low-to-non-detectable activity in control brain. Inhibitor profiling reveals that the glioma 30 kDa
band is sensitive to all tested inhibitor whereas the ~ 25 kDa band is fully sensitive to PMSF and less so to deshiobiotin-FP (DeBi), but resistant to
other tested inhibitors, including MAFP. The gel is representative of two independent ABPP runs with similar outcome. ABHD1, ABHD6, ABHD11,
ABHD12, ABHD16A, α/β-hydrolase domain-containing 1, 6, 11, 12 and 16A; FAAH, fatty acid amide hydrolase; FASN, fatty acid synthase; KIAA1363,
also known as AADACL1 or NCEH1 (neutral cholesteryl ester hydrolase 1); LYPLA1/2, lysophospholipase A1/A2 (also known as acyl-protein
thioesterases 1/2 or APT1/APT2); MAGL, monoacylglycerol lipase; PREP, prolyl oligopeptidase, also known as POP. Image was adjusted for
brightness and contrast
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glioma model shows leaky blood vessels with compro-
mised blood-brain-barrier (BBB) function, especially at
the tumor edge (Figure S1). Sections were stained for
the redox-sensitive marker heme oxygenase-1 (HO-1) to
visualize areas prone to redox stress (Figure S11). A het-
erogeneous pattern of HO-1 staining was evident in the
tumor with no detectable signal in control brain. How-
ever, although HO-1 positive cells localized to regions of
intense SH activity, neither TAMRA-FP hotspots nor
TAMRA-FP hotspot clusters stained strongly for HO-1.
In the absence of truly selective microglial marker, we
stained sections for Iba1 (Figure S12), being aware of
that this marker also labels activated monocytes and
macrophages. We observed heterogeneous presence of
Iba1-positive cells throughout the tumor with intense
staining in tumor margins, and noted partial overlap of
Iba1 staining with TAMRA-FP hotspots. However, no
Iba1-positive cells were evident in tumor regions of
TAMRA-FP hotspot clusters. As expected, Iba1-positive
cells with characteristic microglial morphology were de-
tected in the healthy brain (Figure S12).
SH Activity in Relation to Hyaluronan (HA) – CD44 Axis
and Markers of Tumor Stiffness
Stromal HA accumulation is considered as a protumori-
genic factor in several solid tumors [32, 33]. Extensive
modeling of the extracellular matrix associated with bio-
mechanical changes, often called tumor “stiffness”, is a
hallmark of “cancerized” fibrotic stroma [32]. The HA
receptor CD44 promotes cancer cell motility, tumor
growth, angiogenesis as well as resistance to chemo- and
radiotherapy, and is overexpressed in various tumors, in-
cluding GBM [34]. We clarified whether TAMRA-FP
hotspots localize to tumor regions undergoing matrix re-
modeling using the stiffness markers pMLC2 and tenas-
cin C along with HA and CD44. HA was detected in the
extracellular matrix throughout the brain with more in-
tense staining in glioma, especially the glioma edges
(Figure S13). HA was abundant in areas of TAMRA-FP
hotspots. In contrast, HA was sparse in regions of
TAMRA-FP hotspot clusters, whereas these clusters
were surrounded by HA-enriched tissue. Like HA, CD44
was enriched in the glioma with low expression in nor-
mal brain (Figure S14). Like HA, CD44 was abundant in
glioma regions of TAMRA-FP hotspots but was un-
detectable in regions of TAMRA-FP hotspot clusters, yet
these clusters were surrounded by CD44-positive cells.
pMLC2 showed intense staining over the glioma but was
absent from healthy brain (Figure S15). Interestingly, the
stiffness marker frequently co-localized with TAMRA-
FP hotspots. In contrast, pMLC2-positive cells were rare
in the central part of TAMRA-FP hotspot clusters
whereas TAMRA-FP-positive cells at the edge of these
clusters expressed pMLC2 and were also surrounded by
pMLC2-positive cells. The outcome with tenascin C
(Figure S16) was similar to what was observed with
pMLC2.
SH Activity in Relation to Cells of Myeloid and Lymphoid
Origin
Bone-marrow-derived cell populations are abundant in
tumors, including GBM [30, 31]. In human and rodent
gliomas, tumor-associated macrophages (TAMs) are the
major class of tumor-promoting immune cells and were
also previously detected in this model [29]. We pursued
to identify TAMs and other bone-marrow-derived cells
in glioma. Interestingly, both TAMRA-FP hotspots and
hot spot clusters expressed the hematopoietic marker
CD45 (Figure S17) or the phagocyte marker CD11b/c
(Figure S18). Although macrophages were abundant in
glioma regions showing prominent SH activity, neither
TAMRA-FP hotspots nor TAMRA-FP hotspot clusters
originated from cells stained for the macrophage
markers CD68 (Figure S19), CD163 (Figure S20) or
CD169 (Figure S21). Lymphoid cells were present in gli-
oma regions showing prominent SH activity and
TAMRA-FP hotspots partially overlapped with CD4-
and CD8-positive cells, whereas TAMRA-FP hotspot
clusters sparsely expressed the T-cell markers (Figures
S22 and S23).
Tumor-Associated Mast Cells Partly Account for the High
SH Activity
We found low expression of the mast cell marker FcεRIγ
within TAMRA-FP hotspots whereas FcεRIγ-positive
cells were enriched in TAMRA-FP hotspot clusters,
showing marked co-localization with TAMRA-FP (Fig-
ure S24). Besides mast cells, FcεRIγ labels eosinophils,
basophils and monocytes, so this marker alone cannot
verify the presence of mast cells. Mast cell-specific serine
proteases include tryptases and chymases. We stained
the sections for chymase using CMA1 antibody. Faint
expression of CMA1 was evident in glioma where
CMA1-positive cells co-localized with TAMRA-FP hot-
spots, whereas CMA1-positive cells were scarce in
TAMRA-FP hotspot clusters (Figure S25). Unfortu-
nately, we found no additional antibodies that qualified
for further verification of mast cell presence. Further, at-
tempts to detect mast cells by enzymo-histochemical
staining of serine protease activity using peptide sub-
strates tailored for human tryptase and chymase [35]
were unsuccessful (data not shown).
Tumor-Associated Neutrophils (TANs) Largely Account for
Tumor SH Activity Hotspots
Neutrophils encompass four serine proteases (NSPs),
namely neutrophil elastase (NE), cathepsin G (CTSG),
proteinase 3 (PR3), and neutrophil proteinase 4 (NSP4,
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also known as PRSS57) [13, 36]. We stained glioma sec-
tions for the neutrophil marker myeloperoxidase (MPO)
and found that MPO-positive cells localized to TAMRA-
FP hotspots (Fig. 4). Further, MPO-positive cells were
abundant in TAMRA-FP hotspot clusters (Fig. 4). The
outcome was essentially the same in sections stained for
the NSP elastase (Fig. 5).
Noteworthy, high-resolution fluorescence imaging re-
vealed that TAMRA-FP hotspots had the morphological
characteristics of neutrophil-type multi-nucleated cells
(Fig. 6). Importantly, TAMRA-FP labeling of these cells
was sensitive to the SH inhibitors PMSF and DeBi-FP,
indicating that TAMRA-FP fluorescence in the glioma
hotspots and hotspot clusters indeed represents SH
activity.
In sham-operated animals, TAMRA-FP hotspots with
TAN-like morphology were rare at the site of injection
(Figure S26), indicating that the surgical operation per
se did not cause TAN accumulation. Collectively these
findings indicated that TANs represent the principal
cell-type accounting for TAMRA-FP hotspots and hot-
spot clusters.
ABPP of Glioma Proteome Using Novel Activity Probes
Designed for Human Serine Proteases
In further efforts to characterize glioma serine protease
activity, we utilized newly introduced activity probes
with preference for trypsin and elastase [9] using both
gel- and tissue-based ABPP approaches. These probes
bear a diphenylphosphonate (DPP) warhead, which tar-
gets serine proteases more specifically than the FP war-
head which broadly targets the mSH family [37]. Besides
glioma, we profiled tumor cells and bone-marrow-
derived mononuclear cells (rBM). Interestingly, the
elastase-preferring probe V-DPP detected 3–4 proteins
(~ 25 kDa) in rBM and weakly two bands of similar size
in glioma (Figure S27). Probe binding was sensitive to
SH inhibitors, indicating that V-DPP specifically re-
ported elastase-type serine protease activity. The trypsin-
preferring probe PK-DPP gave no detectable signal in
gel-ABPP (Figure S27). When tested in tissue-ABPP in
place of TAMRA-FP, probe binding was hardly visible
and neither probe labeled inhibitor-sensitive targets in
glioma (Figure S28).
We evaluated also novel activity probes bearing the
DPP warhead that were tailored to report individually
activities of the four human NSPs [13]. Unfortunately,
the NSP-probes did not recognize any TAMRA-FP sen-
sitive bands in gel-ABPP of rat proteomes (Figure S29).
When tested in tissue-ABPP in place of TAMRA-FP, the
NSP-probes readily bound to sections, yet in a non-
specific manner, as probe binding was not prevented by
prior treatment with TAMRA-FP (Figure S29).
As a final step, we used gel-ABPP to assess inhibitor
sensitivity of TAMRA-FP labeled proteins in neutrophils
and rBMs (Figure S30). Only few prominent bands mi-
grating at ~ 25–30 kDa were present in these proteomes
and TAMRA-FP labeling of these bands was inhibited
by PMSF, desthiobiotin-FP and AEBSF, but was largely
resistant to MAFP and IDFP, consistent with the
pharmacology of the ~ 25 kDa glioma band. Compound
22, designed to potently target human CTSG [38], was
inactive in the rat proteomes whereas another CTSG in-
hibitor (CTSG-I) blocked TAMRA-FP labeling of the ~
25 kDa band in both samples. In tissue-ABPP, the inhibi-
tor did not prevent TAMRA-FP labeling of hotspots or
hotspot clusters (Figure S30).
LC-MS/MS Analysis of the Glioma SH Bands Migrating at
~ 25–30 kDa
Gel-pieces encompassing the prominent SH bands in gli-
oma, rBMs and tumor cells were cut after in-gel fluores-
cence scanning and subjected to LC-MS/MS-based
target identification. To facilitate SDS-PAGE separation
of proteins with similar size, proteomes were deglycosyl-
ated prior to TAMRA-FP labeling. The complete LC-
MS/MS data with all identified proteins is available as
Supplementary File 1. Interestingly, neutrophil serine
proteases CTSG (Ctsg), NE (Elane) and PR3 (Prtn3)
were among the SHs present in the ~ 25 kDa gel-pieces
of glioma and bone marrow samples (Fig. 7), in strong
support for findings from tissue-ABPP. Interestingly, the
~ 25–30 kDa gel-pieces encompassed also two MAFP-
sensitive SHs [8], namely PAF-acetylhydrolases 1b2 and
1b3 (PAFAH1b3 and PAFAH1b2). Collectively, our ex-
periments indicate that the MAFP-resistant TAMRA-FP
signal in the tumor is principally due to neutrophil
serine proteases migrating in the ~ 25 kDa band, while
the bulk of MAFP-sensitive activity in glioma is likely
due to PAFAH1b3 and PAFAH1b2.
Discussion
Our study widens the applicability of the chemoproteo-
mic technology to tissue sections, enabling for the first
time high-resolution confocal fluorescence imaging of
family-wide SH activity in anatomically preserved native
cellular environment. Thorough optimization and valid-
ation was provided by parallel gel-based ABPP, extensive
immunohistochemical mapping of TAMRA-FP signal
origin, as well as LC-MS/MS-based target verification.
Collectively all the evidence demonstrates convincingly
that tissue-ABPP faithfully reports SH activity in cryo-
sections at subcellular resolution. We emphasize that it
is the TAMRA-FP labeling combined with immunohis-
tochemistry and DAPI staining, each step utilizing differ-
ent fluorophores with minimal wavelength overlap that
makes tissue-ABPP a remarkably powerful new approach
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to portrait global SH activity in a complex proteome
with preserved cyto-architecture.
The main focus of our studies was to achieve high-
resolution imaging of global SH activity throughout the
glioma microenvironment, necessitating systematic im-
munohistochemical mapping of origins of SH activity
and its localization with cell-type and tissue stiffness
markers. Together with inhibitor-sensitivity of TAMRA-
FP labeling, these experiments provide the key validation
for tissue-ABPP, ruling out the possibility that TAMRA-
FP binding would be nonspecific. Besides illuminating
the complexity of tumor microenvironment, our study
Fig. 4 (See legend on next page.)
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unveiled heightened SH activity in glioma vs. normal
brain and excluded major tumor-associated cells-types
such as TAMs as a source of this activity. Unexpectedly,
immunohistochemistry pinpointed TANs as the princi-
pal cell-type generating SH activity hotspots in glioma.
The activity probe that we used is commercially avail-
able and similar FP-probes have been previously used
and extensively characterized for gel-based ABPP appli-
cations [2, 6, 7]. Furthermore, the coverage of mSH-
family members recognized by the FP-probes is notable
(> 80%) [37]. It could be argued that the use of broad-
spectrum probe complicates interpretation of signals
emerging from cryosections and therefore quenched
probes with limited reactivity would be preferable. How-
ever, such probes are not yet widely available and as our
principal aim was to provide global portrait of SH activ-
ity within the tumor microenvironment, the use of
broad-spectrum probe was fully justified. In analogy, the
vast majority of gel-based ABPP studies prefer to utilize
broad-spectrum probes in order to achieve the global
SH activity profile of the studied proteome. However,
tissue-ABPP studies in future could utilize also newly-
developed activity probes, tailored to target a particular
subset of mSHs [39].
SHs are key regulators of metabolic pathways in dis-
eases including cancer, neurodegenerative diseases,
metabolic syndrome and atherosclerosis. Tissue-ABPP
offers a new tool to explore the myriad roles of SHs
likely play in physiology and disease. We anticipate that
tissue-ABPP should find broad immediate applications.
We applied tissue-ABPP also successfully to spleen sec-
tions, mainly to provide additional validation in native
immune tissue for TAMRA-FP labeling in relation to
some of the antibodies (Figures S31 and S32). Previously,
a single study has presented low-resolution TAMRA-FP
imaging of AEBSF-sensitive SH activity in prostate can-
cer specimen in supplementary figure [40]. Although
preliminary, that work extends the applicability of
tissue-ABPP to human proteomes. As ABPP requires no
a priori knowledge of the identity of the target, we envis-
age no imaginable reason why tissue-ABPP would not
work for sections regardless of species and tissue source.
Both cell morphology and immunohistochemical
evidence implicated neutrophils as the principal cell
type generating TAMRA-FP hotspots and hotspot
clusters in glioma. We emphasize that the hotspots
described here represent SH activity, as TAMRA-FP
labeling was sensitive to the SH inhibitors PMSF and
DeBi-FP (Fig. 6). Furthermore, LC-MS/MS verified
the presence of NSPs in the gel-pieces encompassing
the intense ~ 25 kDa TAMRA-FP bands, allowing to
conclude that NSPs account for the bulk of this activ-
ity. In further support are findings showing that the
elastase-preferring V-DPP-probe detected TAMRA-
FP-sensitive ~ 25 kDa bands in glioma and that neu-
trophil and glioma proteomes shared similarly migrat-
ing intense SH bands with related pharmacology.
Collectively these findings strongly suggest that NSPs
rather than mSHs accounted for the TAMRA-FP hots
spots and hotspot clusters.
The newly developed DPP-activity probes [13] and
CTSG inhibitor Compound 22 [38] were designed to
specifically target human NSPs. In our study, the com-
pounds behaved as expected when tested using human
proteomes (Figure S29 and data not shown). However,
our cross-validation experiments clearly indicated that
the Cy5-probes did not recognize mutual targets with
TAMRA-FP in rat neutrophils or glioma. This was not
totally unexpected, as both probe and inhibitor design
exploited unique substrate recognition sequences around
the catalytic sites which are not necessarily shared be-
tween human and rat NSPs. It is likely that the different
warhead (DPP vs. FP) could also account for major dif-
ferences in the reactivity and sensitivity of these probes
to the inhibitors.
TANs are newcomers at the mainstage of cancer re-
search [41]. In GBM, TANs seem to play mainly a
tumorigenic role [42]. A recent study suggested involve-
ment of TANs in GBM recurrence after radiotherapy by
showing that neutrophils promoted cancer cells stem-
ness [43]. In clinical samples, a positive correlation
existed between neutrophils and patients diagnosed with
recurrent tumor [43]. Future work could elucidate the
role of TANs and NSPs in more detail.
(See figure on previous page.)
Fig. 4 Confocal imaging of SH activity in relation to myeloperoxidase (MPO), a marker for neutrophils. Sections went through the tissue-ABPP
protocol to label SHs (red) and were thereafter immunostained for MPO (yellow), followed by DAPI staining to visualize nuclei (blue). Panel a
shows overall staining pattern throughout the coronal section plane. A control section undergoing identical staining protocol with no primary
antibody is illustrated at top. Panel b shows staining pattern in glioma region characterized by intense SH activity originating from individual cells
(TAMRA-FP hotspots). Panel c shows staining pattern in glioma region characterized by intense SH activity originating from cell clusters (TAMRA-
FP hotspot clusters). Panel d shows staining pattern in healthy brain (cortex). Note detectable expression of MPO in the glioma (a). Note MPO-
positive cells in the region of TAMRA-FP hotspots and marked co-localization of MPO with the TAMRA-FP signal (b). Note abundance of MPO-
positive cells within TAMRA-FP hotspot clusters, as well as close match of MPO staining with TAMRA-FP hotspot clusters (c). MPO is not visible in
control cortical region (d). Primary antibody rabbit anti-MPO (Abcam, cat# ab9535), dilution 1:25, secondary antibody Goat anti-rabbit IgG-Alexa
Fluor 647 conjugate, dilution 1:100. Sections were from female rat 11. Scale bars: 1 mm in a, 20 μm in b-d. Images were adjusted for brightness
and contrast
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Interestingly, the ~ 30 kDa SH was enriched in glioma
and was not detected in healthy brain or neutrophils.
Collectively our tissue and gel-based ABPP experiments
suggested that the majority of the MAFP-sensitive SH
activity in glioma likely reflects activity of the ~ 30 kDa
prominent SH band. LC-MS/MS disclosed PAFAH1b3
and PAFAH1b2, among others, in the gel-pieces encom-
passing the ~ 25–30 kDa TAMRA-FP bands. Note-
worthy, these mSHs are MAFP-sensitive [8] and were
proposed to play protumorigenic role in various cancers
Fig. 5 Confocal imaging of SH activity in relation to neutrophil elastase (NE). Sections went through the tissue-ABPP protocol to label SHs (red)
and were thereafter immunostained for NE (yellow), followed by DAPI staining to visualize nuclei (blue). Panel a shows overall staining pattern
throughout the coronal section plane. A control section undergoing identical staining protocol with no primary antibody was not available for
this experiment. Panel b shows staining pattern in glioma region characterized by intense SH activity originating from individual cells (TAMRA-FP
hotspots). Panel c shows staining pattern in glioma region characterized by intense SH activity originating from cell clusters (TAMRA-FP hotspot
clusters). Panel d shows staining pattern in healthy brain (cortex). Note detectable expression of NE throughout the glioma (a). Note in particular
NE-positive cells in the region of TAMRA-FP hotspots and close match of NE-positive cells with the TAMRA-FP signal (b). Note strong NE-
immunostaining of the TAMRA-FP hotspot clusters and close match of NE staining within the TAMRA-FP hotspot cluster (c). NE is not visible in
control cortical region (d). Primary antibody rabbit anti-NE (Abcam, cat# ab21595), dilution 1:500, secondary antibody Goat anti-rabbit IgG-Alexa
Fluor 647 conjugate, dilution 1:100. Sections were from female rat 11. Scale bars: 1 mm in a, 20 μm in b-d. Images were adjusted for brightness
and contrast
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[44–46]. Future work should elucidate the role of
PAFAH1b3 and PAFAH1b2 in glioma.
The presently used rat gliosarcoma model has been
useful to test novel chemotherapeutic targeting strat-
egies, antitumor effects of gene therapy, anti-angiogenic
agents alone or in combination with radiation and
chemotherapy ([18] and references therein). We chose
this model for convenience as it was previously used by
researchers at our university [29] and the expertise to
execute such studies was readily available.
Gel- and MS-based ABPP has shown that isolated
mouse brain primary cells such as neurons, astrocytes
and microglia each show characteristic SH activity pro-
files [47]. Tissue-ABPP offers a powerful tool for detailed
investigation of this issue in situ with all normal cell
types present. Such studies should be of wide interest to
increase knowledge on the myriad roles that SHs likely
play in the CNS. Based on studies from this and other
laboratories [14, 19–27], gel-ABPP using brain mem-
branes typically detects 20–30 SH bands, depending on
Fig. 6 High-resolution imaging of TAMRA-FP hotspots and TAMRA-FP hotspot clusters and their inhibitor sensitivity in glioma. In a, the upper
panel shows hematoxin-eosin (H&E) stained section. For images in the lower panel, sections went through the tissue-ABPP protocol to label SHs
(red), followed by DAPI staining to visualize nuclei (blue). Note presence of multi-nucleated cells with TAN-like morphology in regions of TAMRA-
FP hotspots and TAMRA-FP hotspot clusters. In b, sections were pretreated with DMSO or with the SH inhibitors PMSF (1 mM) or deshiobiotin-FP
(DeBi-FP, 5 μM) for 1 h at RT, after which they went through the tissue-ABPP protocol to label SHs (red), followed by DAPI staining to visualize
nuclei (blue). Note that throughout the examined regions, TAMRA-FP labeling is sensitive to the inhibitors. Scale bars 10 μm (a) and 20 μm (b).
Images were adjusted for brightness and contrast
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the brain region studied (see e.g. Figure 3). The band in-
tensities vary, reflecting activities of the individual SHs.
Weak or hardly detectable bands set the practical limit
for sensitivity of gel-ABPP. As the majority of mSHs are
expressed in brain [1, 2], only a fraction of these can be
detected using gel-ABPP. By analogy, the situation is
likely similar concerning sensitivity of tissue-ABPP.
However, confocal imaging settings can be adjusted to
optimally capture TAMRA-FP signal also from brain re-
gions showing low fluorescence. Our study indicates that
under the conditions employed, tissue-ABPP should
offer adequate sensitivity to enable imaging of SH activ-
ity not only in the tumor microenvironment but also in
different regions of the healthy brain (Figs. 1 and S33). A
straightforward starting point could be comparative
tissue-ABPP of an individual SH, e.g. the principal endo-
cannabinoid hydrolase MAGL using brain sections of
wild-type and MAGL-deficient mice, as MAGL knock-
out does not lead to compensatory changes in the activ-
ity of other SHs, as evidenced by gel-based ABPP [25].
Competitive tissue-ABPP would offer a complementary
approach for sections where MAGL is chemically
inactivated with highly selective and ultra-potent inhibi-
tors, such as JJKK-048 and KML29 [3, 14].
Conclusions
Our study advances the ABPP approach to tissue sec-
tions, enabling high-resolution confocal fluorescence im-
aging of global SH activity in anatomically preserved
complex native cellular environment. To achieve global
portrait of SH activity throughout the tissue section, we
used a probe with broad reactivity towards the SH family
members. Thorough optimization and validation, com-
plemented by gel-based ABPP, extensive immunohisto-
chemical mapping enabling localization of SH hotspot
activity, combined with LC-MS/MS-based target verifi-
cation, collectively demonstrate that tissue-ABPP faith-
fully reports SH activity in cryosections. Tissue-ABPP is
expected to provide sufficient degree of sensitivity,
allowing profiling of not only heightened SH activity in
the tumor, but also lower levels of SH activities in differ-
ent regions of the healthy brain. As ABPP requires no a
priori knowledge of the identity of the target, we envis-
age no imaginable reason why the presently described
Fig. 7 LC-MS/MS-based identification of the ~ 25–30 kDa SH bands in rat glioma and bone marrow-derived mononuclear cells. Gel-ABPP was
conducted using rat glioma homogenates (rGlioma) or lysates of rat bone marrow-derived mononuclear cells (rBM) as detailed in Materials and
Methods. To facilitate SDS-PAGE separation of proteins with similar size, the proteomes (4 mg/ml) were deglycosylated (+) or underwent control
treatment (−) prior to TAMRA-FP labeling. For deglycosylation, samples were treated with Protein Deglycosylation Mix II (New England Biolabs,
Cat#P6044S) for 1 h at RT as per kit instructions, after which TAMRA-FP labeling was conducted using routine gel-ABPP protocol. Following in-gel
fluorescence imaging, gel-pieces encompassing the SH bands of interest (numbered 1-15x) were cut and subjected to LC-MS/MS analysis, as
described in Materials and Methods. Gel-pieces marked with x were cut as one sample containing also the numbered gel-piece and split
thereafter, yielding two separate samples that were subjected to LC-MS/MS. The SHs identified from the glioma samples (1-7x) are listed in the
middle (blue-white table) and those identified from rBM (8-15x) at right (yellow-white table). Note presence of the NSPs CTSG (Ctsg), NE (elastase
2, Elane) and PR3 (Prtn3) in the ~ 25 kDa gel-pieces of both proteomes. Note also presence of platelet-activating factor acetylhydrolases 1b2 and
1b3 (PAFAH1b3 and PAFAH1b2) in the 25–30 kDa gel-pieces of both proteomes. The complete LC-MS/MS data listing all identified proteins and
additionally data on BT4C glioma cells is available as Supplementary File 1
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approach would not work for sections regardless of spe-
cies and tissue source.
Materials and Methods
The principal aim of this study was to achieve high-
resolution imaging of global SH activity in glioma brain
cryosections throughout the tumor microenvironment,
necessitating systematic mapping of sources of SH activ-
ity by using cell-type specific immunohistochemical
markers. To validate the tissue-ABPP approach, trad-
itional gel-ABPP methodology combined with LC-MS/
MS-based target identification was employed.
Chemicals and Reagents
The following activity probes were used: TAMRA-FP
(ActivX TAMRA-FP serine hydrolase probe, cat# 88318)
and DeBi-FP (ActivX Desthiobiotin-FP Serine Hydrolase
Probe, cat# 88317) were purchased from Thermo Scien-
tific. The Cy5-labeled serine protease probes PK-DPP
and V-DPP bearing a diphenylphosphonate (DPP) war-
head [48] were used in selected experiments (Figures
S27–28). Similarly, the Cy5-labeled NSP probes bearing
a diphenylphosphonate (DPP) warhead [13] were used in
selected experiments (Figure S29).
The following inhibitors were used: AEBSF (Sigma,
cat#A8456), PMSF (Sigma, cat# P7626), IDFP (Cayman
Chemical, cat# 10215), MAFP (Sigma, cat#M2939),
CTSG-I (Calbiochem, cat# 219372). Compound 22 was
obtained from Joakim Swedberg (at that time in the In-
stitute for Molecular Bioscience, University of Queens-
land, Brisbane, Australia).
For immunohistochemistry, various antibodies from
different sources were used. The hyaluronan binding
probe (bHABR) was prepared in-house [49] (Figure
S13). The following secondary antibodies were used:
Goat anti-rabbit IgG-Alexa Fluor 647 conjugate
(Thermo Scientific, cat# A-21245), Donkey anti-mouse
IgG-Alexa Fluor 647 conjugate (Thermo Scientific, cat#
A-31571),
Donkey anti-goat IgG-Alexa Fluor 647 conjugate
(Thermo Scientific, cat# A-21447), and DyLight 488
Steptavidin (Vector Laboratories, cat# SA-5488). Primary
antibody source, dilution used in immunostaining and
choice of secondary antibodies are given in the captions
of the images showing immunostained sections (Figures
S8-S26 and S31-S32). Nuclei were stained with DAPI
(4′,6-diamidino-2-phenylindole) (Sigma, cat# D8417).
The BSA used was essentially fatty acid free (Sigma
cat#A0281). All other chemicals were of highest purity
available.
Cell Culture
BT4C cells were grown in Dulbecco’s modified eagle’s
medium DMEM (EuroClone, high glucose, with stable
L-Glutamine, cat# ECM0103L) supplemented with 10%
FBS (Euroclone, cat# ECS0180L) in a humidified cell
culture incubator with 5% CO2 environment. The cells
were maintained and sub-cultured two-three times a
week at 1:6 splitting ratio. For preparation of the cell
suspension for rat malignant glioma model, cells were
trypsinized and collected in normal culture media
(DMEM supplemented with 10% FBS) followed by a
brief centrifugation at 1000 rpm, for 4 min at 4 °C, and
re-suspended in fresh OPTI-MEM®I reduced serum
medium (Gibco, cat# 31985–062). Cells were then
counted and diluted in the same medium to 2 × 106
cells/ml so that each 5 μl of cell suspension contained
approximately 10,000 cells. For collecting cell pellets,
cells were grown in several T-175 flasks until they be-
come 95% confluent. On the day of collection, the cell
culture media was aspirated from each flask, washed
with cold 1xPBS, and cells were collected mechanically
by using cell lifter/scraper in presence of 5 ml of cold 1x
PBS. Cell fractions collected from different flasks were
then combined into a 50ml conical tube, washed with
1xPBS, centrifuged at low speed (300×g, for 10 min at
4 °C) to obtain opaque cell pellet. The pellet was stored
at − 80 °C.
Animals
Malignant Rat Glioma Model
In total 34 BDIX rats (18 males and 16 females, Envigo,
Huntingdon, UK) weighing 127–267 g were used. The
rats were anesthetized i.p. with ketamine (Ketalar®, 60
mg/kg) and medetomidine (Domitor®, 0.4 mg/kg) and
placed in a stereotactic apparatus. After skin incision, a
hole was drilled 1 mm posterior to the bregma and to
the 2 mm right of sagittal suture. 10,000 BT4C tumor
cells in 5 μl of OPTI-MEM®I reduced serum medium
were injected with a Hamilton syringe within right cor-
pus callosum (depth 2.5–3.0 mm). To avoid backflow,
the injection was done slowly over 2–3 min. The needle
was left in place for 2 min and then slowly removed.
Skin incision was closed with stiches followed by s.c. in-
jections of antisedative (atipamezole, Antisedan®, 1 mg/
kg) and analgesic (carprofen, Rimadyl®, 5 mg/kg). Con-
trol rats were processed similarly, except that cells were
omitted and only OPTI-MEM®I reduced serum medium
was inoculated.
Tissue Harvesting from Glioma Animals
The rats were sacrificed 28–38 days after inoculation of
the cells (the rats bearing tumors 28–31 days after in-
oculation). Animals were stunned with CO2 and then
transcardially perfused with PBS. From majority of the
rats, the whole brain was removed, dipped briefly in cold
(− 80 °C) isopentane and stored on dry ice. From six rats
in total, the tumor and corresponding brain piece from
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contralateral cerebral hemisphere were separated and
were frozen on dry ice. For bone marrow collection,
total of four bones (Tibia, Femur, Humerus, and Radius)
were collected from each animal and stored in cold 1x
PBS for further processing.
Control Rats Used for Harvesting Immune Cells and Tissue
For collecting rat spleens, cerebella, and fresh blood as
the source of neutrophils, 10–12 week-old male Rcc:Han
WIST rats (Laboratory Animal Centre, University of
Eastern Finland) were used. Rats were decapitated and
blood was collected with a funnel into a 50ml conical
tube soaked with EDTA (1.5–1.8 mg/ml of fresh blood).
The blood was then processed within 2 h of collection.
The cerebella were dissected, dipped briefly in cold (−
80 °C) isopentane and stored on dry ice. The spleens
were collected, frozen on dry ice and then stored at −
80 °C.
Mice Used in Preliminary Tissue-ABPP Experiments
To test fixatives and TAMRA-FP concentrations during
tissue-ABPP method optimization (Figures S4–S5), 4-
week-old male JAXC57BL/6 J mice (Laboratory Animal
Centre, University of Eastern Finland) were used. Mice
were decapitated, the whole brain was removed, dipped
briefly in cold (− 80 °C) isopentane and frozen on dry ice
and then stored at − 80 °C.
MRI
Magnetic resonance imaging (MRI) was used to verify
tumor existence 12–14 and 22–24 days after inoculation
of the cells. Anesthesia was induced with 5% isoflurane
in a mixture of 70:30% N2O:O2 and was maintained at
1.5% isoflurane. MRI scanning was done with a 7 T Bru-
ker PharmaScan system and ParaVision® 5.1 software
(Bruker, Billerica, MA, USA). Turbo-RARE imaging se-
quence with the following parameters was used: TE 12.5
ms/50 ms, TR 4000ms, RARE factor 8, FOV 2 cm,
256 × 256 matrix, slice thickness 1 mm with 15 slices.
The images were processed with a home-build Matlab
program Aedes (University of Eastern Finland).
Cryosectioning
Coronal rat brain sections, horizontal mouse brain sec-
tions and rat spleen sections (20 μm thick) were cut at −
19 °C to − 21 °C using a Leica cryostat (Leica Biosystems,
IL, USA). The sections (3 sections per slide) were thaw-
mounted onto Superfrost®Plus slides (Menzel-Gläser,
Germany), dried for 1–3 h at RT under a constant
stream of air and stored thereafter at − 80 °C. Rat and
mouse brain sections were cut according to Rat Brain
Atlas (Paxinos & Watson 1998).
Tissue-ABPP
Tissue-ABPP was used either for imaging SH activity
alone or in combination with immunohistochemistry
and nuclear staining, as detailed below.
Protocol for Imaging SH Activity
The assay was performed at RT (20–22 °C) unless other-
wise stated. Generally, the fixing and all washing steps
were performed in large volume (~ 200 ml) by dipping
the slides into indicated buffer. Other steps of the proto-
col were performed by pipetting the indicated volume of
buffer on the sections and by incubating the slides in a
humidified chamber placed on a low-speed horizontal
shaker.
The slides (3 tissue sections per slide) were thawed
under a constant stream of air and thereafter each sec-
tion was lined with a mini PAP pen (Fisher Scientific,
cat# 10464573). The slides were fixed with 4% parafor-
maldehyde (PFA) supplemented with 0.01% glutaralde-
hyde in 0.1M phosphate buffer (pH 7.4) for 10 min and
rinsed thereafter 2 × 5 min in 1xPBS. The assay protocol
consisted of preincubations 2 × 10 min in the assay buf-
fer (250 μl/section) containing 50 mM Tris-HCl, pH 7.4;
1 mM EDTA; 100 mM NaCl; 5 mM MgCl2 and 0.1% (w/
v) BSA, followed by 60min incubation in the assay buf-
fer (250 μl/section) in the presence of inhibitors or 1%
(v/v) DMSO as a solvent. After washes 3 × 1 min in the
assay buffer (250 μl/section), the slides were incubated
for 60 min with TAMRA-FP in the assay buffer (95 μl/
section, routinely 0.5 μM final concentration) and there-
after washed 3 × 10 min in 0.1M phosphate buffer (pH
7.4). In some experiments, Cy-5 labelled probes were
used instead of TAMRA-FP as detailed in Figures S28
and S29. In preliminary experiments, presented in Fig-
ures S1 and S4-S5, the slides were dried under constant
stream of air and imaged thereafter using a Fuji gel scan-
ner. In subsequent experiments, the slides were further
stained with nuclear stain DAPI (2 μg/ml in 0.1 M phos-
phate buffer, 300 μl/section) for 15 min at 37 °C and
washed 2 × 5 min with 0.1M phosphate buffer (pH 7.4).
Finally, the slides were embedded with Vectashield®
Antifade mounting medium (cat# H-1000, Vector la-
boratories, CA, USA).
Tissue-ABPP Combined with Immunohistochemistry and
Nuclear Staining
When immune markers were used, the preceding proto-
col for TAMRA-FP labeling is the same as described
above. The TAMRA-FP labeled sections were washed
5 × 5 min with 1xPBS supplemented with 1% (w/v) BSA
(210 μl/slide). The sections were incubated overnight
with primary antibody (195 μl/slide) at 4 °C, washed 3 ×
10 min with 0.1M phosphate buffer (pH 7.4) followed by
60min incubation with secondary antibody (195 μl/
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slide). Both primary and secondary antibodies were di-
luted in 1xPBS supplemented with 1% (w/v) BSA. Fi-
nally, the slides were washed 3 × 5 min with 0.1M
phosphate buffer (pH 7.4), stained with DAPI (2 μg/ml,
300 μl/slide) for 15 min at 37 °C, washed 2 × 5 min with
0.1M phosphate buffer (pH 7.4) and embedded with
Vectashield® Antifade mounting medium.
Histology
To visualize tumor morphology, the sections were fist
fixed with 4% PFA supplemented with 0.01% glutaralde-
hyde and then stained with Mayer’s hematoxylin and
eosin. Imaging was performed with a Zeiss Axio Imager




For gel imaging and overview of tissue-ABPP slides,
ChemiDoc™ MP imaging system (Bio-Rad, Hercules, CA,
USA) was used. To visualize TAMRA-FP, Cy3 blot ap-
plication (602/50, Green Epi) was used. For Cy5 probes
or immunostained sections, Cy5 blot application (700/
50, Red Epi) was used. In the early phase of this study
(Figures S1, S4-S5), TAMRA-FP-labeled sections were
imaged using Fuji gel scanner (λex 552 nm/λem 575 nm).
Confocal Microscopy
The confocal microscope images were obtained with a
Zeiss Axio Observer inverted microscope (10x, 40x (oil)
or 63x (oil) -objectives) equipped with LSM800 confocal
module (Carl Zeiss Microimaging GmbH, Jena,
Germany). TAMRA-FP, DAPI, and secondary antibodies
were imaged with 561 nm (λex 543 nm/λem 567 nm), 405
nm (λex 353 nm/λem 465 nm), and 640 nm (λex 653 nm/
λem 668 nm) lasers, respectively. Secondary antibody
used with bHABR (Figure S13) was imaged with 488 nm
(λex 495 nm/λem 519 nm) laser. ZEN 2.3 (Blue) and ZEN
2.3 lite softwares (Carl Zeiss Microimaging GmbH) were
utilized for image processing and image analysis.
Rat Bone Marrow Cell Isolation
For bone marrow collection, total four bones (Tibia,
Femur, Humerus, and Radius) were collected from each
animal removing extra materials covering these bones,
and stored in cold 1xPBS. The tip of each bone was cut
with scissors, and flushed into a 50ml conical tube with
ice-cold 1xPBS using a 25G-needle, until no red color
was visible. The sample was then homogenized using a
pipette, filtered through Corning® cell strainer (CORN-
ING, cat# 431750, 40 μm nylon), and centrifuged at
443×g for 4 min at 4 °C to pellet the cells, and suspended
in 4 ml of 1xPBS. Four ml of ice cold ficoll-paque plus
(GE Healthcare, 17–1440-02, density 1.077 ± 0.001 g/ml)
was pipetted into a 10ml transparent tube, and bone
marrow cells (4 ml) were then overlaid on top of ficoll-
paque plus carefully avoiding mixing of the two layers,
then centrifuged at 443×g, 20 °C for 40 min without-
brake in a swinging bucket centrifuge. The mononuclear
cells were collected from the interface of PBS (top layer),
and Ficoll-Red blood cells with granulocytes (two bot-
tom layers). The cells were then washed by adding 3–6
volumes of 1xPBS followed by centrifugation at 1560×g
for 4 min at 4 °C to remove extra Ficoll. The solid-white
pellets were then stored at − 80 °C.
Human and Rat Blood Neutrophil Isolation
For the isolation of neutrophils from human and rat
blood, we used ficoll-paque plus (GE Healthcare, cat#
17–1440-02, Density 1.077 ± 0.001 g/ml) density gradient
protocol adapted from [50, 51]. Human and rat samples
were handled separately. Briefly, fresh blood samples
were collected from 5 rats (~33 ml) and a human donor
(~12 ml) in sodium EDTA (1.5–1.8 mg/ml of fresh
blood). Five ml of blood was overlaid carefully on 5.0 ml
of ficoll-paque plus in a 15 ml conical tube, centrifuged
at 500×g for 35 min at RT with brake off. The
granulocyte-rich pellet was collected by removing three
upper layers (plasma, mononuclear cells, and remaining
ficoll-paque plus), and processed further by preparing 1x
HBSS-buffer (LONZA, BioWhittaker, cat# 04-315Q)
suspension, 3% (w/v) dextran (Dextran T500, Pharmacia,
cat# 17–0320-01, 450,000–550,000M.W.) sedimentation,
collecting granulocyte-enriched supernatant to a new
tube; sample was centrifuged (300×g for 10 min at RT)
and after removing the supernatant, remaining erythro-
cytes were lysed using hypotonic buffer, re-equilibrated
to restore isotonicity, followed by centrifugation (300×g
for 10 min at RT). Final washing and centrifugation
(300×g for 10 min at RT) was done using HBSS buffer,
resulting to clear white pellet. The pellet was stored at −
80 °C.
Preparation of Proteomes for Gel-Based ABPP
Cell pellet was thawed in ice, and 100-500 μl of 1xPBS
was added to each tube depending on the size of the pel-
let (approximately 1 mm-sized pellet in height, was re-
suspended in 100 μl of 1xPBS), mixed properly, spun,
and went through freeze-thaw lysis procedure for at least
five cycles (freezing at − 80 °C for 15 min or on dry ice
for 5 min, thawing at 37 °C water bath for 1 min). Tissue
samples were thawed in ice, weighted and required
amount of 50 mM Tris-HCl, pH 7.4 + 150 mM NaCl buf-
fer was added based on 1ml volume per 1 g wet tissue-
ratio, homogenized in glass-glass homogenizer in ice.
The samples were collected into separate 2 ml Eppen-
dorf tubes after washing with double volume of the Tris-
buffer used initially. Finally, homogenized tissue samples
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and freeze-thaw-treated cell suspensions were sonicated
on ice to obtain completely homogenized samples. Sam-
ples were then aliquoted, protein concentration was de-
termined using BCA-200 Protein Assay Kit (PIERCE,
23226) as per company’s protocol, and stored at − 80 °C.
Rat cerebellar membranes were prepared as previously
described [52].
Competitive Gel-Based ABPP
Competitive gel-ABPP was conducted using the Cy3-
labeled probe TAMRA-FP or in selected experiments
(Figures S28 and S29) various Cy5-labeled serine prote-
ase probes, following general outlines of our previous
publication [53]. Briefly, 25 μl of proteomes (5–10 μg
protein) diluted in PBS were preincubated with the indi-
cated inhibitors (50-fold desired final concentration) or a
vehicle (DMSO) for 1 h at RT, followed by addition of
activity probe (in the case of TAMRA-FP, final concen-
tration was 1 μM). The reaction was quenched by adding
2xSDS-loading buffer, followed by protein separation by
SDS-PAGE (10%). For some lanes, Precision Plus Pro-
tein™ standards (BIO-RAD, cat# 161–0373) were in-
cluded. In early phase of this study, TAMRA-FP
fluorescence was imaged using Fujifilm FLA-3000 laser
fluorescence scanner (Fujifilm, Tokyo, Japan) (Fluor.
532 nm; Filter: O580 nm). Thereafter, ChemiDoc™ MP
imaging system (BIO-RAD, Hercules, California, USA)
was used as follows: Cy3 blot application (602/50, Green
Epi, Manual Exposure 10s–120s) was used, and Cy5 blot
application (700/50, Red Epi, Manual Exposure 1 s) was
used to image MW markers and all Cy5-labelled probes.
Sample Preparation for LC-MS/MS
Gel casting and ABPP were done with special care in
order to minimize potential contamination by foreign
proteins. Gel electrophoresis and imaging was as de-
scribed above. As TAMRA-FP labelling is visible only in
imager under specific wavelength, the cutting of
intended bands was done by keeping gel in a new, clear
square BioAssay Dish (Corning, cat# 431111, 245 mmx
245mm) put on a horizontally positioned computer
screen where the imaged picture was opened and posi-
tioned accurately (as accurate as possible). The gel
pieces was cut using scalpel no. 11 and collected into la-
belled 1.5 ml Eppendorf tube. The cut gel was then im-
aged again to check the accuracy of sample collection
(Supplementary File 1_LC-MS-MS data). Collected sam-
ples were then wrapped with Parafilm®, stored in − 80 °C
freezer, and shipped to Helsinki proteomics lab in dry
ice contained box.
LC-MS/MS Analysis
Protein bands were cut out of the polyacrylamide gel
(Bio-Rad, USA) and “in-gel” digested cystein bonds were
reduced with 0,045M dithiothreitol (Sigma, cat# D0632)
for 20 min at 37 °C and alkylated with 0,1 M iodoaceta-
mide (Sigma-Aldrich, cat# 57670) at room temperature.
Samples were digested by adding 0,75 μg trypsin (Se-
quencing Grade Modified Trypsin, V5111, Promega).
After digestion peptides were purified with C18 micro-
spin columns (Harvard Apparatus) according to manu-
factures protocol and re-dissolved in 30 μl.
Liquid chromatography coupled to tandem mass spec-
trometry (LC-MS/MS) analysis was carried out on an
EASY-nLC1000 (Thermo Fisher Scientific, Germany)
connected to a Velos Pro-Orbitrap Elite hybrid mass
spectrometer (Thermo Fisher Scientific, Germany) with
nano electrospray ion source (Thermo Fisher Scientific,
Germany). The LC-MS/MS samples were separated
using a two-column setup consisting of a 2 cm C18-A1
trap column (Thermo Fisher Scientific, Germany),
followed by 10 cm C18-A2 analytical column (Thermo
Fisher Scientific, Germany). The linear separation gradi-
ent consisted of 5% buffer B in 5 min, 35% buffer B in
60min, 80% buffer B in 5 min and 100% buffer B in 10
min at a flow rate of 0,3 μl/min (buffer A: 0,1% TFA in
1% acetonitrile; buffer B: 0,1% TFA acid in 98% aceto-
nitrile). 6 μl of sample was injected per LC-MS/MS run
and analyzed. Full MS scan was acquired with a reso-
lution of 60,000 at normal mass range in the orbitrap
analyzer the method was set to fragment the 20 most in-
tense precursor ions with CID (energy 35). Data was ac-
quired using LTQ Tune software.
Acquired MS2 scans were searched against Rattus nor-
vegicus protein data-base using the Sequest search
algorithms in Thermo Proteome Discoverer. Allowed
mass error for the precursor ions was 15 ppm. And for
the fragment in 0,8 Da. A static modification parameter
was set for carbamidomethyl + 57,021 Da (C) of cysteine
residue. Methionine oxidation (+ 15,995 Da (M)) and
TAMRA-FP (+ 659,312 Da (S, Y)) were set as dynamic
modifications. Only full-tryptic peptides were allowed
for scoring maximum of 1 missed cleavages were
considered.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12575-020-00118-4.
Additional file 1 : Figure S1. Activity-based protein profiling (ABPP)
and the power of this approach to unveil SH activity in glioma. Figure
S2. Characteristics of the rat BT4C gliosarcoma model. Figure S3. Cor-
onal plane MRI images of glioma and control brains. Figure S4. Testing
various fixation method for rodent brain sections. Figure S5. Effect of
TAMRA-FP concentration on fluorescence signal in mouse brain sections.
Figure S6. Effects of pH and buffer composition on TAMRA-FP signal
and its inhibitor sensitivity. Figure S7. Comparative gel-based ABPP of
seven animals confirming distinct SH activity profiles between glioma
and control brain. Figure S8. Confocal imaging of SH activity in relation
to proliferating tumor cells. Figure S9. Confocal imaging of SH activity in
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relation to astrocytes. Figure S10. Confocal imaging of SH activity in re-
lation to blood vessels. Figure S11. Confocal imaging of SH activity in
relation to heme oxygenase 1 (HO-1). Figure S12. Confocal imaging of
SH activity in relation to microglial marker Iba1. Figure S13. Confocal im-
aging of SH activity in relation to hyaluronan (HA). Figure S14. Confocal
imaging of SH activity in relation to HA receptor CD44. Figure S15. Con-
focal imaging of SH activity in relation to the stiffness marker pMLC2. Fig-
ure S16. Confocal imaging of SH activity in relation to the stiffness
marker tenascin C. Figure S17. Confocal imaging of SH activity in rela-
tion to CD45, a marker for nucleated hematopoietic cells. Figure S18.
Confocal imaging of SH activity in relation to CD11b/c, a marker for
phagocytes. Figure S19. Confocal imaging of SH activity in relation to
CD68, a marker for monocytes and macrophages. Figure S20. Confocal
imaging of SH activity in relation to CD163, a marker for monocytes and
macrophages. Figure S21. Confocal imaging of SH activity in relation to
CD169, a marker for macrophages. Figure S22. Confocal imaging of SH
activity in relation to T cell marker CD4. Figure S23. Confocal imaging of
SH activity in relation to T cell marker CD8. Figure S24. Confocal im-
aging of SH activity in relation to FcεRIγ, a marker for mast cells, eosino-
phils, basophils and monocytes. Figure S25. Confocal imaging of SH
activity in relation to chymase (CMA1), a marker for mast cells. Figure
S26. TAMRA-FP signal at the site of injection in sham-operated animals.
Figure S27. Gel-ABPP of rat glioma proteomes using Cy5-labeled serine
protease activity probes PK-DPP and V-DPP. Figure S28. Tissue-ABPP of
glioma sections using Cy5-labeled activity probes PK-DPP and V-DPP. Fig-
ure S29. ABPP of rat neutrophil and glioma samples using Cy5-labeled
neutrophil serine protease (NSP) probes in combination with TAMRA-FP.
Figure S30. Inhibitor profiles of human cathepsin G (hCTSG) and the
prominent 25–30 kDa SH bands in rat bone-marrow-derived mononuclear
cells and neutrophils. Figure S31. High-resolution imaging of TAMRA-FP
hotspots and their inhibitor sensitivity in rat spleen. Figure S32. Confocal
imaging of SH activity in rat spleen sections in relation to selected immu-
nomarkers. Figure S33. Tissue-ABPP offers sufficient sensitivity to enable
imaging of TAMRA-FP fluorescence in regions of the healthy brain.
Additional file 2 Video S1. 3D-animation of merged TAMRA-FP-DAPI
fluorescence throughout the section thickness in TAMRA-FP hotspots and
TAMRA-FP hotspot clusters (related to Fig. 1).
Additional file 3. Complete LC-MS/MS data of all proteins identified
from the ABPP gel-pieces.
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